EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Impact of CD151 overexpression on prognosis and therapy in non‐small cell lung cancer patients lacking EGFR mutations

Amanda Huee-Ping Wong iD, Min En Nga, Chin Yein Chin, Yee Kit Tai, Hung Chew Wong, Ross Soo, Omer An iD, Henry Yang, Ju Ee Seet, Yaw Chyn Lim, John Kit Chung Tam iD, Thai Tran iD

Cell Proliferation · 2024

DOI: 10.1111/cpr.13708 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cell Proliferation, 2024. Verfasst von Amanda Huee-Ping Wong und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Physiology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Tetraspanin 24, ErbB Receptors, Lung Neoplasms. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 55 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National University Health Systems Bench-to-bedside grant, NUHS Cross Department Collaborative Grant.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

This study investigates CD151, a protein linked to cancer progression, in non‐small cell lung cancer (NSCLC) patients without epidermal growth factor receptor (EGFR) mutations. These patients often have limited treatment options. The study used retrospective analysis to examine 157 adenocarcinoma biopsy specimens and 199 patient cases from The Cancer Genome Atlas, correlating CD151 expression with patient survival. Cellular studies revealed that CD151 interacts with EGFR, influencing epidermal growth factor (EGF)‐induced cell proliferation and the effectiveness of the EGFR inhibitor, erlotinib. A strong association was found between CD151 expression and EGFR mutation status. High CD151 expression in the absence of EGFR mutations is correlated with poorer survival outcomes. Biological assays showed that CD151 colocalizes and associates with EGFR, playing a crucial role in regulating EGF‐induced cell proliferation via the AKT and ERK1/2 pathways. Importantly, CD151 expression was found to influence the anti‐proliferative effects of the EGFR tyrosine kinase inhibitor, erlotinib. High CD151 expression, in the absence of EGFR mutations, was associated with poorer survival outcomes. It could serve as a potential prognostic marker and influence cellular responses to EGFR‐targeted treatments. This study highlights CD151 as a potential novel target for therapeutic intervention in NSCLC, especially in populations lacking EGFR mutations.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungTetraspanin 24ErbB ReceptorsLung NeoplasmsMutationErlotinib HydrochlorideCell ProliferationHumansPrognosisFemaleMaleCell Line, TumorMiddle AgedRetrospective StudiesProtein Kinase InhibitorsAged

Substanzen

Tetraspanin 24ErbB ReceptorsCD151 protein, humanErlotinib HydrochlorideEGFR protein, humanProtein Kinase Inhibitors

Autor:innen und Institutionen

  • Department of Physiology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore.
  • Department of Pathology, National University Hospital, Singapore, Singapore.
  • Department of Pathology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore.
  • Department of Biostatistics, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore.
  • Department of Haematology-Oncology, National University Hospital, Singapore, Singapore.
  • Cancer Science Institute of Singapore, National University of Singapore, Singapore, Singapore.

ORCID-Profile: Amanda Huee-Ping Wong, Omer An, John Kit Chung Tam, Thai Tran

Förderung

  • National University Health Systems Bench-to-bedside grant
  • NUHS Cross Department Collaborative Grant

Zitieren

APA

Wong, A. H., Nga, M. E., Chin, C. Y., Tai, Y. K., Wong, H. C., Soo, R., An, O., Yang, H., Seet, J. E., Lim, Y. C., Tam, J. K. C., & Tran, T. (2024). Impact of CD151 overexpression on prognosis and therapy in non‐small cell lung cancer patients lacking EGFR mutations. Cell Proliferation. https://doi.org/10.1111/cpr.13708

Vancouver

Wong AH, Nga ME, Chin CY, Tai YK, Wong HC, Soo R, et al. Impact of CD151 overexpression on prognosis and therapy in non‐small cell lung cancer patients lacking EGFR mutations. Cell Proliferation. 2024. doi:10.1111/cpr.13708

BibTeX
@article{Wong2024,
  author = {Wong, Amanda Huee-Ping and Nga, Min En and Chin, Chin Yein and Tai, Yee Kit and Wong, Hung Chew and Soo, Ross and An, Omer and Yang, Henry and Seet, Ju Ee and Lim, Yaw Chyn and Tam, John Kit Chung and Tran, Thai},
  title = {Impact of CD151 overexpression on prognosis and therapy in non‐small cell lung cancer patients lacking EGFR mutations},
  journal = {Cell Proliferation},
  year = {2024},
  doi = {10.1111/cpr.13708}
}
Kostenlos starten →